03
AUG
2010
Long-Term Follow-Up Of DCVax®-Treated Brain Cancer Patients Shows 33% Of Patients Reached 4-Year Survival And 27% Have Reached Or Exceeded 6-Year Survival
Comments : Off
BETHESDA, MD – August 3, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme (“GBM”), the most rapid and lethal type of brain cancer, were treated with NWBT’s DCVax®-Brain personalized immune therapy. The data through July 1, 2010, show that... Read More